Following a broad audit of bond trustees’ conduct, the Israel Securities Authority published Legal Position 108-5 on September 22, 2024, clarifying trustees’ duties toward bondholders. While a trustee may generally rely on company representations and professional opinions, the Position states that in certain cases this isn’t enough – trustees must take independent, active steps, such as obtaining more information and reviewing valuations on their own. Notably, a trust deed cannot exempt a trustee from these duties. The Position focuses on four areas: collateral changes, financial covenant compliance, early redemption calculations, and controlling-shareholder transaction approvals.
Following a broad audit conducted by the Israel Securities Authority (the “ISA”) of the conduct of bond trustees in relation to companies that have issued bonds to the public, on September 22, 2024 the ISA published Legal Position No. 108-5 (the “Position”). The Position is intended, among other things, to address the duties applicable to corporations that have issued bonds to the public, including their duties toward bondholders and toward the trustee for bondholders.
As a rule, a trustee may rely, among other things, on representations and confirmations provided by the company, on a review of the disclosure in the company’s reports, or on professional opinions submitted to it by the company. That said, under the Position, in certain cases this will not be sufficient, and in order to fulfill its duties the trustee will be required to take additional, active and independent steps that are not dependent on the company’s representations (such as obtaining supplementary information, requiring detailed reasoning, and independently reviewing representations, opinions, and valuations). Accordingly, companies and trustees may not exempt trustees from these duties (or from any other duty) by way of exceptions set out in the trust deed. For example, the parties may not provide in the trust deed that the trustee will rely solely on the company’s representations and confirmations and will be exempt from taking any further action.
The Position highlights several points that are relevant for issuing companies:
Beyond the above, the Position also addresses: